FDA Pushes Potential Approval For Cytokinetics’ Experimental Heart Drug By Three Months

All NewsMay 2, 2025

FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent